Imaging cell death for early detection of treatment efficacy
Today, there is intensive ongoing research for clinical tools that can accurately measure the effect of cancer therapy as early as possible since it creates opportunities to personalize treatments. An effective way is measuring cell death instead of volumetric and morphometric changes in response to therapy. Molecular changes occur much faster and with the right target and imaging technique, this can show superior sensitivity and specificity for assessing the effectiveness of a therapy.
The authors of this publication use 99mTc-duramycin instead of 99mTc-Annexin V to image and quantify in vivo cell death. By using the MILabs’ U-SPECT/CT system, they were able to demonstrate that in animal models, 99mTc-duramycin has a more favorable pharmacokinetic profile than Annexin V tracers, thus raising the chances for a successful translation to the clinic.
Early prediction of tumor response to treatment:
Pre-clinical validation of 99mTc-duramycin
Elvas et al., J. Nucl. Med., 2016
U-SPECT image demonstrates excellent apoptopic response in two tumors shortly after treatment with a combination of two chemotherapy agents.
This publication utilizes the MILabs U-SPECTTM imaging system for high resolution in vivo validation and quantification of 99mTc-duramycin, validated by histology and autoradiography.
Imaging and quantitation results demonstrated the potential of 99mTc-duramycin for early monitoring of treatment response, using a human colorectal cancer model treated with both chemo- and radiotherapy, and combinations of both.
MILabs products are used in more than 65 countries and are supported by a global network of distributors and factory trained support engineers.
Please contact MILabs directly for more information about your local MILabs business partner.